Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database
Copyright © 2023 Alorfi, Alshehri and Haseeb..
Background: Monkeypox (mpox), a zoonotic viral infection, poses a global threat that is being acknowledged at the national and international levels. This systematic review aims to identify and characterize interventional clinical trials for mpox.
Method: All interventional clinical trials registered at ClinicalTrials.gov for mpox were searched up to January 6, 2023. We described the characteristics of interventional clinical trials, and drug interventions (including drugs and vaccines).
Results: As of January 6, 2023, there were 10 clinical trials in the ClinicalTrials.gov registry that met our criteria. Most of the interventional clinical trials were focused on the treatment (N = 4, 40%) and prevention (N = 4, 40%) of mpox. From the 10 trials, 50% used random treatment allocation, and six (60%) chose the parallel assignment intervention model. All 10 studies were blinded, and six were open-label blinded. The largest proportion of the clinical trials (N = 4, 40%) were registered in Europe, followed by America (N = 3, 30%) and Africa and others (N = 3, 30%). The JYNNEOS vaccine (40%), followed by Tecovirimat (30%) were the most frequently studied drugs used against mpox.
Conclusion: A limited number of clinical trials have been registered on ClinicalTrials.gov since the first case of mpox was reported. Therefore, there is an urgent need to conduct large-scale randomized clinical trials to assess the safety and efficacy of the drugs and vaccines being used against the mpox virus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in public health - 11(2023) vom: 21., Seite 1144325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alorfi, Nasser M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Benzamides |
|---|
| Anmerkungen: |
Date Completed 28.03.2023 Date Revised 13.12.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fpubh.2023.1144325 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354746812 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354746812 | ||
| 003 | DE-627 | ||
| 005 | 20231227131157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fpubh.2023.1144325 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM354746812 | ||
| 035 | |a (NLM)36969617 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alorfi, Nasser M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Alorfi, Alshehri and Haseeb. | ||
| 520 | |a Background: Monkeypox (mpox), a zoonotic viral infection, poses a global threat that is being acknowledged at the national and international levels. This systematic review aims to identify and characterize interventional clinical trials for mpox | ||
| 520 | |a Method: All interventional clinical trials registered at ClinicalTrials.gov for mpox were searched up to January 6, 2023. We described the characteristics of interventional clinical trials, and drug interventions (including drugs and vaccines) | ||
| 520 | |a Results: As of January 6, 2023, there were 10 clinical trials in the ClinicalTrials.gov registry that met our criteria. Most of the interventional clinical trials were focused on the treatment (N = 4, 40%) and prevention (N = 4, 40%) of mpox. From the 10 trials, 50% used random treatment allocation, and six (60%) chose the parallel assignment intervention model. All 10 studies were blinded, and six were open-label blinded. The largest proportion of the clinical trials (N = 4, 40%) were registered in Europe, followed by America (N = 3, 30%) and Africa and others (N = 3, 30%). The JYNNEOS vaccine (40%), followed by Tecovirimat (30%) were the most frequently studied drugs used against mpox | ||
| 520 | |a Conclusion: A limited number of clinical trials have been registered on ClinicalTrials.gov since the first case of mpox was reported. Therefore, there is an urgent need to conduct large-scale randomized clinical trials to assess the safety and efficacy of the drugs and vaccines being used against the mpox virus | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a immunity | |
| 650 | 4 | |a monkeypox | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a viral | |
| 650 | 7 | |a Benzamides |2 NLM | |
| 700 | 1 | |a Alshehri, Fahad S |e verfasserin |4 aut | |
| 700 | 1 | |a Haseeb, Abdul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in public health |d 2013 |g 11(2023) vom: 21., Seite 1144325 |w (DE-627)NLM23377548X |x 2296-2565 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g day:21 |g pages:1144325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fpubh.2023.1144325 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |b 21 |h 1144325 | ||